Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer

PURPOSE: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic RCC. However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment for both patients with TKI naïve or resistant RCC. EXPERIMENTAL DESIGN: I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Zhang, Liang, Wang, Xiaoen, Bullock, Andrea J., Callea, Marcella, Shah, Harleen, Song, Jiaxi, Moreno, Kelli, Visentin, Barbara, Deutschman, Douglas, Alsop, David C., Atkins, Michael B., Mier, James W., Signoretti, Sabina, Bhasin, Manoj, Sabbadini, Roger A., Bhatt, Rupal S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4419371/
https://ncbi.nlm.nih.gov/pubmed/25589614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados